ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0693

Discovery of Antigen Specific CD4+ T Cells in Anti-HMGCR-positive Immune Mediated Necrotizing Myopathy

Eleni Tiniakou1, Andrew Mammen2 and Erika Darrah1, 1Johns Hopkins University, Baltimore, MD, 2National Institutes of Health, Bethesda, MD

Meeting: ACR Convergence 2021

Keywords: Dendritic cells, Myositis, proteomics, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Muscle Biology, Myositis & Myopathies Poster (0683–0722)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR)-positive immune mediated necrotizing myopathy (anti-HMGCR+ IMNM) is a unique myopathy characterized by IgG autoantibodies against HMGCR and a strong association with a specific HLA class II allele (HLA-DRB1*11:01). Although this implicates HMGCR-specific CD4+ T cells in disease pathogenesis, no such cells have been identified thus far. In this study, we aimed to define HMGCR T cell epitopes using a natural antigen processing assay (NAPA).

Methods: Monocyte-derived dendritic cells (MoDCs) from 6 patients with anti-HMGCR+ IMNM were incubated with the C-terminal portion of HMGCR protein (amino acids 340-888) and presented peptides were identified using NAPA. Briefly, HLA-DR/peptide complexes were isolated by immunoprecipitation, and bound HMGCR peptides were sequenced by mass spectrometry. HMGCR peptides corresponding to the putative CD4+ T cell epitopes were synthesized and used to stimulate peripheral blood mononuclear cells (PBMCs) from 6 patients with anti-HMGCR+ IMNM and 6 patients with dermatomyositis, as negative controls. HMGCR-reactive CD4+ T cells were identified by flow cytometry based on activation status (CD154 upregulation).

Results: A total of 7 different naturally processed HMGCR peptides were identified using NAPA (Table 1). The number of distinct peptides presented per patient ranged from 1 to 5, with 5 epitopes being presented by at least two patients. All naturally presented HMGCR peptides elicited robust CD4+ T cell responses in the 6 anti-HMGCR+ IMNM patients, compared to only 2/6 patients with dermatomyositis (p=0.014). All anti-HMGCR+ IMNM patients responded to 3-7 peptides (median 5.5) (Figure 1), and the T cell responses were significantly higher than those observed in patients with dermatomyositis (p< 0.0001).

Conclusion: Our findings represent the first report of antigen-specific CD4+ T cells in anti-HMGCR+ IMNM. Leveraging NAPA, we were able to define a core set of HMGCR peptides naturally presented by MoDCs from patients with anti-HMGCR+ IMNM, defining precise immunologically relevant autoantigenic CD4+ T cell epitopes. Definition of these epitopes is key in understanding disease pathogenesis and will aid in the future development of antigen-specific research and therapeutic tools.

Table 1. Naturally processed HMGCR peptides identified by mass spectrometry. The naturally processed HMGCR peptides presented by each patient are indicated (+ = detected, – = not detected my mass spectrometry).

Figure 1. Anti-HMGCR+ IMNM patient T-cell responses to naturally processed HMGCR peptides. PBMCs from 6 anti-HMGCR+ IMNM patients were stimulated with the HMGCR peptides identified by NAPA and the % of CD4+CD54+ T cells above background observed with media alone was measured. Positive responses were considered those above the 95th percentile of the response of dermatomyositis (DM) controls (dotted line).


Disclosures: E. Tiniakou, None; A. Mammen, None; E. Darrah, None.

To cite this abstract in AMA style:

Tiniakou E, Mammen A, Darrah E. Discovery of Antigen Specific CD4+ T Cells in Anti-HMGCR-positive Immune Mediated Necrotizing Myopathy [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/discovery-of-antigen-specific-cd4-t-cells-in-anti-hmgcr-positive-immune-mediated-necrotizing-myopathy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/discovery-of-antigen-specific-cd4-t-cells-in-anti-hmgcr-positive-immune-mediated-necrotizing-myopathy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology